BIOIBÉRICA
9.3.2017 11:38:25 CET | Business Wire | Press release
“Everybody has heard of penicillin, but nobody knows what heparin is. And the fact is that heparin has saved as many lives as penicillin in the course of the 20 th century ”, explains Prof. Coen Hemker , a biochemist and Emeritus of the University of Maastricht, at the start of the documentary “Heparin: 100 years saving lives” . This 30-minute audiovisual recording has been directed by Carles Canet and produced by Broadcaster , with promotion from Bioibérica , to describe – on the basis of personal experiences – this anticoagulant drug which is so important in modern Medicine, having been declared a first-need drug by the World Health Organization.
In effect, this is the first documentary dedicated to this drug, and has been able to join the leading specialists and investigators in Hematology, Cardiology and Surgery, among other fields, as well as the drug industry, within one same audiovisual recording. Professionals from Spain (Hospital de la Santa Creu i Sant Pau , Hospital Universitari General de Catalunya , Hospital Germans Trias i Pujol , Banc de Sang i Teixits , Instituto Valenciano de Fertilidad , ISGlobal , IBEC ), the United States (Baylor University , Rensselaer Polytechnic Institute ), The Netherlands (Universidad de Maastricht , Synapse Research Institute ) and Italy (Instituto Ronzoni ), as well as international companies such as Sanofi , Laboratorios Rovi , BBraun or Bioibérica , have participated in the initiative
But the true central characters of this documentary are the patients who explain their own experiences: “I found it impossible to finish a training session and couldn’t believe that I would have to abandon water polo because of a clot in the subclavian vein at 17 years of age. Thanks to heparin, I was able to recover after six months, and everything that came afterwards was very much worthwhile”, explains Jennifer Pareja , a Spanish water polo player nominated the best player in the world in 2013.
The documentary can be seen online on Bioiberica website and is open to all those entities, educational institutions, organizations and people who wish to use and diffuse the recording. “Five out of every 10 people will need heparin at some point in life. Medicine wouldn’t be where it is today without it ”, explains Professor James Marcum , a historian at Baylor University in the United States.
Heparin , discovered in 1916, is a highly sulfated glycosaminoglycan – a natural substance composed of various molecules that inhibits blood clotting. Because of these properties, heparin is currently the most widely used drug for preventing and treating thrombosis. According to the International Society on Thrombosis and Hemostasis , one out of every four people in the world die of causes related to this disorder , which now produces more deaths each year than AIDS, breast cancer and traffic accidents combined.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005559/en/
Contact:
Bioibérica
Alba Soler i Conangla
+34 682 04 07
76 / +34 93 490 49 08
Communications Director
asoler@bioiberica.com
Visit
our press room
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 19:06:00 CET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 18:00:00 CET | Press release
SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
